RenovoRx, Inc. (RNXT)
- Previous Close
1.4300 - Open
1.4300 - Bid 1.0400 x 200
- Ask 1.8000 x 200
- Day's Range
1.3700 - 1.4584 - 52 Week Range
0.5310 - 3.2900 - Volume
10,635 - Avg. Volume
37,604 - Market Cap (intraday)
34.751M - Beta (5Y Monthly) 1.07
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9900 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.83
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
renovorx.comRecent News: RNXT
Performance Overview: RNXT
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RNXT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RNXT
Valuation Measures
Market Cap
33.77M
Enterprise Value
32.60M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.37k
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-163.15%
Return on Equity (ttm)
-646.98%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-10.23M
Diluted EPS (ttm)
-0.9900
Balance Sheet and Cash Flow
Total Cash (mrq)
1.17M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-5.44M
Research Analysis: RNXT
Company Insights: RNXT
RNXT does not have Company Insights